Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'

This article was originally published in The Pink Sheet Daily

Executive Summary

Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.

You may also be interested in...



Oncology In 21st Century Cures: Heading Toward A Two-FDA Solution?

The 21st Century Cures Act regulatory reform provisions amount to a lot of little things: tweaks to encourage ongoing activities rather than bold departures at a time when the overall regulatory climate is good for innovators. But the law could also be the start of something bigger – a more formal division within the US FDA between oncology and everything else.

NIH Funding Component of 21st Century Cures May Get White House Boost

Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.

Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps

Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS079568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel